G. Kees Hovingh

12 ta ish

University of Amsterdam

1. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

   Antonio J. Vallejo‐Vaz, Christophe Stevens, Alexander R.M. Lyons +97

   MaqolaOAOchiq kirish20215 iqtibos

   ABIABI:AkademIndex/2026.other.072451

2. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration

   Antonio J. Vallejo‐Vaz, Asif Akram, Sreenivasa Rao Kondapally Seshasai +69

   MaqolaOAOchiq kirish20163 iqtibos

   ABIABI:AkademIndex/2026.other.011186

3. Clinical Genetic Testing for Familial Hypercholesterolemia

   Amy C. Sturm, Joshua W. Knowles, Samuel S. Gidding +29

   Sharh maqolaOAOchiq kirish20183 iqtibos

   ABIABI:AkademIndex/2026.other.057740

4. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

   Kanika Dharmayat, Antonio J. Vallejo‐Vaz, Christophe Stevens +97

   MaqolaOAOchiq kirish20233 iqtibos

   ABIABI:AkademIndex/2026.other.233436

5. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

   M. Cuchel, Éric Bruckert, H. N. Ginsberg +41

   Maqola20143 iqtibos

   ABIABI:AkademIndex/2026.other.535421

6. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

   Erik S.G. Stroes, Paul D. Thompson, Alberto Corsini +37

   Sharh maqola20153 iqtibos

   ABIABI:AkademIndex/2026.other.568881

7. EU-Wi<i>d</i>e Cross-Section<i>a</i>l Obser<i>v</i>at<i>i</i>o<i>n</i>al Study of Lipid-Modifying Therapy Use in Se<i>c</i>ondary and Pr<i>i</i>mary Care: the DA VINCI study

   Kausik K. Ray, Bart Molemans, W. Marieke Schoonen +28

   Maqola20203 iqtibos

   ABIABI:AkademIndex/2026.other.661379

8. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

   Antonio J. Vallejo‐Vaz, Martina De Marco, Christophe Stevens +82

   MaqolaOAOchiq kirishLipoproteins and Cardiovascular HealthAtherosclerosis20182 iqtibos

   ABIABI:AkademIndex/2018.article.000004

9. Familial hypercholesterolaemia: A global call to arms

   Antonio J. Vallejo‐Vaz, Sreenivasa Rao Kondapally Seshasai, Della Cole +44

   MaqolaOAOchiq kirish20152 iqtibos

   ABIABI:AkademIndex/2026.other.011143

10. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome

    Barbara Sjouke, D. Meeike Kusters, Iris Kindt +10

    MaqolaOAOchiq kirish20142 iqtibos

    ABIABI:AkademIndex/2026.other.011146

11. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

    Paul M. Ridker, Matt Devalaraja, Florian M.M. Baeres +9

    MaqolaOAOchiq kirish20212 iqtibos

    ABIABI:AkademIndex/2026.other.216651

12. Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry

    Amany Elshorbagy, Antonio J. Vallejo‐Vaz, Fotios Barkas +80

    MaqolaOAOchiq kirishLipoproteins and Cardiovascular HealthEuropean Heart Journal20251 iqtibos

    ABIABI:AkademIndex/2025.article.000498